RxDoctor Payments Data

Urwa Barakat, MD

Interventional Cardiology · Warren, OHNPI 1124132691

Payments from drug & device makers

$679in general payments, 2019–2025

Across 25 payments — averaging $27.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$245
  • Amarin Pharma, Inc.$113
  • Sanofi-aventis U.S. LLC$111
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$110
  • Novartis$28
  • Pfizer$23
  • plus $50 from 3 others

What the payments were for

  • Food & beverage$679100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$679 in reported general payments places this provider in the 15th percentile of 256 interventional cardiology providers in Ohio.

See all interventional cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$157,793
Medicare patients
627
Services billed
2,262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban381$438,112
EntrestoSacubitril/Valsartan117$133,487
XareltoRivaroxaban101$103,621
JardianceEmpagliflozin48$49,075
BrilintaTicagrelor34$28,600
Repatha SureclickEvolocumab30$21,005
Metoprolol Succinate781$11,797
Repatha SyringeEvolocumab12$6,558
Bumetanide86$3,355
Potassium Chloride173$3,111
Amiodarone Hcl149$2,924
ClopidogrelClopidogrel Bisulfate297$2,906
Ranolazine ErRanolazine29$2,901
Atorvastatin Calcium306$2,617
Midodrine Hcl19$2,535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$438,112381 claims
NovartisEntresto$28$133,487117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 256 interventional cardiology providers in Ohio.

Other interventional cardiology in Warren

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →